BG101355A - Вирусен материал и нуклеотидни фрагменти, свързани с диагностика, профилактика и лечение на мултиплената склероза - Google Patents

Вирусен материал и нуклеотидни фрагменти, свързани с диагностика, профилактика и лечение на мултиплената склероза

Info

Publication number
BG101355A
BG101355A BG101355A BG10135597A BG101355A BG 101355 A BG101355 A BG 101355A BG 101355 A BG101355 A BG 101355A BG 10135597 A BG10135597 A BG 10135597A BG 101355 A BG101355 A BG 101355A
Authority
BG
Bulgaria
Prior art keywords
sequences
thisdisease
multiplesclerosis
prophylaxy
diagnostics
Prior art date
Application number
BG101355A
Other languages
English (en)
Other versions
BG62977B1 (bg
Inventor
Herve Perron
Frederic Beseme
Frederic Bedin
Glaucia Paranhos-Baccala
Florence Komurian-Pradel
Colette Jolivet-Reynaud
Bernard Mandrand
Original Assignee
Bio Merieux
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bio Merieux filed Critical Bio Merieux
Publication of BG101355A publication Critical patent/BG101355A/bg
Publication of BG62977B1 publication Critical patent/BG62977B1/bg

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/70—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving virus or bacteriophage
    • C12Q1/701—Specific hybridization probes
    • C12Q1/702—Specific hybridization probes for retroviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/10022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Virology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Analytical Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Physics & Mathematics (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Rheumatology (AREA)
  • Pathology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Neurology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Oncology (AREA)
  • Pain & Pain Management (AREA)
  • Communicable Diseases (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)

Abstract

Изобретението се отнася до вирусен материал в изолирано или пречистено състояние, чийто геном съдържа нуклеотидна последователност, избрана от последователностите SEQ ID Х 46, 51, 52, 53 и 56 и техните комплементарни и еквивалентни последователности. По-специално нуклеотидните последователности проявяват за всяка поредица от 100 непрекъснати мономера поне 50%, по-специално поне 70%, хомоложност спосочените последователности, съответно SEQ ID Х 46, 51, 52, 53 и 56, и техните комплементарни последователности.
BG101355A 1995-08-03 1997-03-25 Вирусен материал и нуклеотидни фрагменти, свързани с диагностика, профилактика и лечение на мултиплената склероза BG62977B1 (bg)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR9509643A FR2737500B1 (fr) 1995-08-03 1995-08-03 Materiel viral et fragments nucleotidiques associes a la sclerose en plaques, a des fins de diagnostic, prophylactiques et therapeutiques
PCT/FR1996/001244 WO1997006260A1 (fr) 1995-08-03 1996-08-02 Materiel viral et fragments nucleotidiques associes a la sclerose en plaques, a des fins de diagnostic, prophylactiques et therapeutiques

Publications (2)

Publication Number Publication Date
BG101355A true BG101355A (bg) 1997-12-30
BG62977B1 BG62977B1 (bg) 2000-12-29

Family

ID=9481811

Family Applications (1)

Application Number Title Priority Date Filing Date
BG101355A BG62977B1 (bg) 1995-08-03 1997-03-25 Вирусен материал и нуклеотидни фрагменти, свързани с диагностика, профилактика и лечение на мултиплената склероза

Country Status (19)

Country Link
US (4) US6001987A (bg)
EP (2) EP0789077B1 (bg)
JP (2) JP4444372B2 (bg)
AT (2) ATE374252T1 (bg)
AU (1) AU730080B2 (bg)
BG (1) BG62977B1 (bg)
BR (1) BR9606566A (bg)
CA (1) CA2201282C (bg)
CZ (1) CZ135797A3 (bg)
DE (1) DE69637264T2 (bg)
ES (2) ES2379011T3 (bg)
FR (1) FR2737500B1 (bg)
HU (1) HUP9900425A3 (bg)
IS (1) IS4455A (bg)
NO (1) NO971493L (bg)
NZ (1) NZ316080A (bg)
PL (1) PL319512A1 (bg)
SK (1) SK56797A3 (bg)
WO (1) WO1997006260A1 (bg)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2737500B1 (fr) * 1995-08-03 1997-08-29 Bio Merieux Materiel viral et fragments nucleotidiques associes a la sclerose en plaques, a des fins de diagnostic, prophylactiques et therapeutiques
US7241876B2 (en) 1996-01-11 2007-07-10 Corixa Corporation Compositions and methods for the therapy and diagnosis of breast cancer
US8043835B1 (en) 1996-03-26 2011-10-25 Oncomedx, Inc. Methods for detecting and monitoring cancer using extracellular RNA
US6329179B1 (en) * 1996-03-26 2001-12-11 Oncomedx, Inc. Method enabling use of extracellular RNA extracted from plasma or serum to detect, monitor or evaluate cancer
US6759217B2 (en) * 1996-03-26 2004-07-06 Oncomedx, Inc. Method enabling use of extracellular RNA extracted from plasma or serum to detect, monitor or evaluate cancer
US7785842B2 (en) * 1996-03-26 2010-08-31 Oncomedx, Inc. Comparative analysis of extracellular RNA species
EP0960210A4 (en) * 1996-10-04 2004-06-09 Chronix Biomedical DIAGNOSTIC NUCLEIC ACID DETECTION
CA2272845C (en) * 1996-11-26 2010-01-12 Bio Merieux Viral material and nucleotide fragments associated with multiple sclerosis, for diagnostic, prophylactic and therapeutic purposes
US8440396B2 (en) * 1997-03-14 2013-05-14 Oncomedx, Inc. Method enabling use of extracellular RNA extracted from plasma or serum to detect, monitor or evaluate cancer
US20070009934A1 (en) * 1997-03-14 2007-01-11 Kopreski Michael S Method enabling use of extracellular RNA extracted from plasma or serum to detect, monitor or evaluate cancer
FR2762601B3 (fr) * 1997-04-29 1999-06-04 Bio Merieux Polypeptide capable de reagir avec les anticorps de patients atteints de sclerose en plaques et utilisations
FR2762600B1 (fr) * 1997-04-29 1999-11-05 Bio Merieux Polypeptide capable de reagir avec les anticorps de patients atteints de sclerose en plaques et utlisations
FR2765588A1 (fr) 1997-07-07 1999-01-08 Bio Merieux Materiel nucleique retroviral et fragments nucleotidiques notamment associes a la sclerose en plaques et/ou la polyarthrite rhumatoide, a des fins de diagnostic, prophylactiques et therapeutiques
US20040176314A1 (en) * 1997-07-07 2004-09-09 Bio Merieux Endogenetic retroviral sequences, associated with autoimmune diseases or with pregnancy disorders
ATE346153T1 (de) * 1997-07-07 2006-12-15 Bio Merieux Endogene retrovirale sequenzen, verwandten mit auto-immune krankheiten oder mit schwangerschaftsstörungen
JP2002511277A (ja) * 1998-04-08 2002-04-16 エムエス・リサーチ・アクティーゼルスカブ 多発性硬化症および他の脱髄性疾患の診断
FR2780069B1 (fr) * 1998-06-23 2002-06-28 Inst Nat Sante Rech Med Famille de sequences nucleiques et de sequences proteiques deduites presentant des motifs retroviraux endogenes humains et leurs applications
US8163524B2 (en) * 1998-09-22 2012-04-24 Oncomedx, Inc. Comparative analysis of extracellular RNA species
US20060204989A1 (en) * 1998-09-22 2006-09-14 Kopreski Michael S Comparative analysis of extracellular RNA species
US20080261292A1 (en) * 1998-09-22 2008-10-23 Oncomedx, Inc. Method Enabling the Use of Extracellular Ribonucleic Acid (RNA) Extracted from Plasma or Serum to Detect, Monitor or Evaluate Cancer or Premalignant Conditions
FR2788784A1 (fr) 1999-01-21 2000-07-28 Bio Merieux Fragment nucleique endogene associe a une maladie auto-immune, procede de marquage et reactif
EP1029917A1 (en) * 1999-02-15 2000-08-23 Bio Merieux The LTR region of MSRV-1 and the proteins it encodes, and probes and methods for detecting MSRV-1 retrovirus
JP2003507070A (ja) * 1999-08-20 2003-02-25 キュラジェン コーポレイション 活性化ｔリンパ球において発現される新規なポリヌクレオチドおよびそれによってコードされるタンパク質
DE10012875B4 (de) * 2000-03-16 2004-04-01 Infineon Technologies Ag Mobilfunkempfänger
CA2403815A1 (en) * 2000-03-21 2001-09-27 Ms Research A/S An infective endogenous retrovirus in association with demyelinating diseases e.g. multiple sclerosis
WO2003009806A2 (en) * 2001-07-25 2003-02-06 Oncomedx Inc. Methods for evaluating pathologic conditions using extracellular rna
US20030104454A1 (en) * 2001-11-05 2003-06-05 Kopreski Michael S. Method for detection of DNA methyltransferase RNA in plasma and serum
US20100159464A1 (en) * 2001-11-05 2010-06-24 Oncomedx, Inc. Method for Detection of DNA Methyltransferase RNA in Plasma and Serum
US20090136942A1 (en) * 2007-09-18 2009-05-28 Oncomedx, Inc. Analysis of Extracellular RNA
WO2010030931A1 (en) * 2008-09-11 2010-03-18 The United States Of America, As Represented By The Secretary, Department Of Health & Human Services Oligonucleotides targeting human endogenous retrovirus 9 (erv-9) long terminal repeat (ltr) and methods of use

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5871996A (en) 1994-02-04 1999-02-16 Bio Merieux Retrovirus agents MSRV1 and MSRV2 associated with multiple sclerosis
WO1980000412A1 (en) * 1978-08-24 1980-03-20 N Gilmour Pasteurellosis vaccines
US4311686A (en) * 1979-04-30 1982-01-19 The Immunology Development Corporation Methodology for the immunodiagnosis of multiple sclerosis and/or malignant diseases from blood sample analysis
US4396600A (en) * 1980-12-18 1983-08-02 Gus Gallucci Adult schistosome worm-derived antigenic substance and method of obtaining same
US4388298A (en) * 1982-07-14 1983-06-14 The United States Of America As Represented By The Secretary Of Agriculture Propagation of hemorrhagic enteritis virus in a turkey cell line and vaccine produced
GB8324800D0 (en) * 1983-09-15 1983-10-19 Pasteur Institut Antigens
US4520113A (en) * 1984-04-23 1985-05-28 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Serological detection of antibodies to HTLV-III in sera of patients with AIDS and pre-AIDS conditions
US4647773A (en) * 1984-04-23 1987-03-03 The United States Of America As Represented By The Department Of Health And Human Services Method of continuous production of retroviruses (HTLV-III) from patients with AIDS and pre-AIDS
NZ218050A (en) * 1985-11-13 1989-05-29 Wistar Inst Test for the presence of htlv-1v
US4900553A (en) * 1987-09-11 1990-02-13 Case Western Reserve University Method of reducing glial scar formation and promoting axon and blood vessel growth and/or regeneration through the use of activated immature astrocytes
EP0326395A2 (en) * 1988-01-29 1989-08-02 City Of Hope Method of detecting and identifying certain viral sequences
FR2651581B1 (fr) * 1989-09-06 1994-05-13 Centre Nal Recherc Scientifique Moyens pour le diagnostic de neuropathies demyelinisantes, en particulier de la sclerose en plaques.
US5219837A (en) * 1990-06-21 1993-06-15 Trustees Of The University Of Pennsylvania Method of stimulating myelination of cells
US5158976A (en) * 1990-10-29 1992-10-27 The Children's Medical Center Corporation Controlling glutamine/glutamate related neuronal injury
JP3602530B2 (ja) * 1991-03-07 2004-12-15 ヴァイロジェネティクス コーポレイション 遺伝子操作したワクチン菌株
DK173091D0 (da) * 1991-10-11 1991-10-11 Schleroseforeningen The Danish Biologisk materiale
FR2689520B1 (fr) 1992-04-03 1996-07-19 Bio Merieux Procede et milieu de culture pour l'obtention de cellules infectees par un virus associe a la sclerose en plaques.
FR2689521B1 (fr) * 1992-04-03 1996-07-19 Bio Merieux Procede d'obtention et maintien d'une culture cellulaire viable, infectee par un virus associe a la sclerose en plaques, et produits biologiques derives de ladite culture.
EP0642585B1 (en) * 1992-05-18 2005-12-28 Genentech, Inc. Activation of oligomerizing receptors by using fused receptor ligands
GB9310657D0 (en) * 1993-05-24 1993-07-07 Univ London Retrovirus
US5580766A (en) * 1994-01-14 1996-12-03 Alexion Pharmaceuticals, Inc. Retroviral vector particles for transducing non-proliferating cells
US5691147A (en) * 1994-06-02 1997-11-25 Mitotix, Inc. CDK4 binding assay
US5710037A (en) * 1994-06-10 1998-01-20 The United States Of America As Represented By The Department Of Health And Human Services Retroviral vector particles
FR2731356B1 (fr) * 1995-03-09 1997-04-30 Bio Merieux Virus msrv-1 et agent pathogene et/ou infectant msrv-2 associes a la polyarthrite rhumatoide
FR2737500B1 (fr) * 1995-08-03 1997-08-29 Bio Merieux Materiel viral et fragments nucleotidiques associes a la sclerose en plaques, a des fins de diagnostic, prophylactiques et therapeutiques

Also Published As

Publication number Publication date
US20070117189A1 (en) 2007-05-24
JP2010047604A (ja) 2010-03-04
EP1916304A3 (fr) 2008-05-07
DE69637264D1 (de) 2007-11-08
FR2737500A1 (fr) 1997-02-07
CA2201282C (fr) 2013-04-02
CA2201282A1 (fr) 1997-02-20
ES2379011T3 (es) 2012-04-19
US6001987A (en) 1999-12-14
JP4444372B2 (ja) 2010-03-31
DE69637264T2 (de) 2008-06-26
HUP9900425A2 (hu) 1999-05-28
NO971493D0 (no) 1997-04-02
ATE541933T1 (de) 2012-02-15
SK56797A3 (en) 1998-09-09
ES2293645T3 (es) 2008-03-16
AU730080B2 (en) 2001-02-22
HUP9900425A3 (en) 1999-11-29
IS4455A (is) 1997-03-26
BG62977B1 (bg) 2000-12-29
US7932350B2 (en) 2011-04-26
EP0789077A1 (fr) 1997-08-13
EP1916304B1 (fr) 2012-01-18
BR9606566A (pt) 1997-12-30
FR2737500B1 (fr) 1997-08-29
WO1997006260A1 (fr) 1997-02-20
NZ316080A (en) 1999-04-29
NO971493L (no) 1997-06-03
ATE374252T1 (de) 2007-10-15
CZ135797A3 (cs) 1998-06-17
EP0789077B1 (fr) 2007-09-26
JPH11502416A (ja) 1999-03-02
EP1916304A2 (fr) 2008-04-30
US20030186391A1 (en) 2003-10-02
JP5143814B2 (ja) 2013-02-13
US6579526B1 (en) 2003-06-17
PL319512A1 (en) 1997-08-18
AU6823296A (en) 1997-03-05

Similar Documents

Publication Publication Date Title
BG101355A (bg) Вирусен материал и нуклеотидни фрагменти, свързани с диагностика, профилактика и лечение на мултиплената склероза
BG101384A (bg) Нови пестицидни белтъци и щамове
WO1994001548A3 (en) Human nucleic acid fragments, isolated from brain adrenal tissue, placenta or bone narrow
ATE128189T1 (de) Hybridizierungssonden von dem abstand zwischen den 16s und 23s rna genen und nachweis von nicht- viralen mikroorganismen.
HU9501963D0 (en) 7-deazapurine modified oligonucleotides
AU6871398A (en) Method for enhancing expression of a foreign or endogenous gene product in pla nts
HK1008347A1 (en) Dorsal tissue affecting factor and compositions
EP1037999A4 (en) POLYPEPTIDES AND NUCLEOTIDES PORPHYROMONAS GINGIVALIS
AU5120796A (en) DNA fragment, recombination vector containing the same and method for expressing foreign genes using the same
WO1999028439A3 (fr) Erythrovirus et ses applications
GB9310657D0 (en) Retrovirus
GB9526178D0 (en) Novel polynuceotides and polypeptides in pathogenic mycobacteria and their use as diagnostics,vaccines and targets for chemotherapy
ZA961349B (en) Amplifying sequences vectors comprising these sequences and their uses in compositions for the expression of nucleotide sequences in transfected cells therapeutic and vaccine applications
AU8447098A (en) Endogenetic retroviral sequences, associated with autoimmune diseases or with pregnancy disorders
ATE335091T1 (de) Bc200 rna, daraus abgeleitete proben und entsprechende anwendungen
HUP0001857A2 (hu) Bakteriális plazmidok
ZA99236B (en) Orotidine-5'-phosphate decarboxylase gene, gene construct comprising this gene and its use.
MXPA01004291A (es) Antigenos de chlamydia y fragmentos de acido desoxirribonucleico correspondientes y usos de los mismos.
IL129368A0 (en) Immunogenic TLP composition
WO1999002666A3 (fr) Materiel nucleique retroviral et fragments nucleotidiques notamment associes a la sclerose en plaques et/ou la polyarthrite rhumatoide, a des fins de diagnostic, prophylactiques et therapeutiques
DE59410427D1 (en) Endothelinkonversionsenzym (ece)
GB9609261D0 (en) Gene expression in monocytes and microphages
WO1998032849A3 (en) Polynucleotide associated with the bo or bor syndrome, its corresponding polypeptide and diagnostic and therapeutic applications
WO1997014798A3 (de) Polynukleotide und die durch diese kodierrte proteine, geeignet zur bekämpfung von melolontha sp.käfern
CA2191624A1 (en) Dna fragment, recombinant vector containing the same and method for expressing foreign genes using the same